| Nome |
# |
|
Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System, file e1dcb337-c798-7715-e053-1705fe0a6cc9
|
539
|
|
Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System, file e1dcb337-e6de-7715-e053-1705fe0a6cc9
|
518
|
|
Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system, file e1dcb337-6139-7715-e053-1705fe0a6cc9
|
469
|
|
Dapagliflozin and cardiovascular outcomes: anything else to DECLARE?, file e1dcb336-78d5-7715-e053-1705fe0a6cc9
|
206
|
|
Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems, file e1dcb339-e747-7715-e053-1705fe0a6cc9
|
173
|
|
Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across Europe., file e1dcb332-756f-7715-e053-1705fe0a6cc9
|
118
|
|
Strategies for early prediction and timely recognition of drug-induced liver injury: The case of cyclin-dependent kinase 4/6 inhibitors, file e1dcb333-f48d-7715-e053-1705fe0a6cc9
|
106
|
|
Gender-differences of in vitro colonic motility after chemo- and radiotherapy in humans, file e1dcb332-4474-7715-e053-1705fe0a6cc9
|
98
|
|
Long-acting injectable antipsychotics: Six-month follow-up of new outpatient treatments in Bologna Community Mental Health Centres, file e1dcb332-9652-7715-e053-1705fe0a6cc9
|
96
|
|
Recurrence of pericarditis after influenza vaccination: a case report and review of the literature, file e1dcb331-d6bb-7715-e053-1705fe0a6cc9
|
89
|
|
Ex vivo effect of vascular wall stromal cells secretome on enteric ganglia, file e1dcb334-0487-7715-e053-1705fe0a6cc9
|
89
|
|
Pro-arrhythmic potential of oral antihistamines (H1): Combining adverse event reports with drug utilization data across Europe, file e1dcb32d-4e3f-7715-e053-1705fe0a6cc9
|
78
|
|
Drug development for the irritable bowel syndrome: current challenges and future perspectives., file e1dcb32c-492b-7715-e053-1705fe0a6cc9
|
64
|
|
Pattern of drug use among preterm neonates: Results from an Italian neonatal intensive care unit, file e1dcb32f-4c6b-7715-e053-1705fe0a6cc9
|
56
|
|
Pharmacovigilance assessment of the association between Fournier's gangrene and other severe genital adverse events with SGLT-2 inhibitors, file e1dcb333-c9ff-7715-e053-1705fe0a6cc9
|
54
|
|
Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis, file e1dcb32e-6c28-7715-e053-1705fe0a6cc9
|
43
|
|
Observational research on sodium glucose co-transporter-2 inhibitors: A real breakthrough?, file e1dcb331-8ba1-7715-e053-1705fe0a6cc9
|
43
|
|
Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance, file e1dcb336-bed1-7715-e053-1705fe0a6cc9
|
34
|
|
Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System, file eaca171a-ce1e-41f6-8a42-667f6cbdd357
|
26
|
|
Development of a Network-Based Signal Detection Tool: The COVID-19 Adversome in the FDA Adverse Event Reporting System, file cf7d8fc4-5a7e-40a8-a176-6b5dab7929fe
|
22
|
|
Strategies and Tools for Supporting the Appropriateness of Drug Use in Older People, file 463640af-159b-41c1-b35f-8828f6a7a1f8
|
20
|
|
Deliberate Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System, file 4c1ab21e-4a86-468f-b565-8fdfefa93759
|
18
|
|
Animal models of chemically induced intestinal inflammation: Predictivity and ethical issues, file e1dcb32c-42b1-7715-e053-1705fe0a6cc9
|
18
|
|
Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across Europe., file e1dcb332-7570-7715-e053-1705fe0a6cc9
|
18
|
|
Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across Europe., file e1dcb332-7571-7715-e053-1705fe0a6cc9
|
16
|
|
Ceftolozane/tazobactam exposure in critically ill patients undergoing continuous renal replacement therapy: a PK/PD approach to tailor dosing, file e1dcb335-f4d5-7715-e053-1705fe0a6cc9
|
16
|
|
Drug repurposing in the covid-19 era: Insights from case studies showing pharmaceutical peculiarities, file c8ab7b1c-d59b-4730-a2f0-51cb734ae8e2
|
15
|
|
Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System, file e1dcb339-4063-7715-e053-1705fe0a6cc9
|
15
|
|
Liver Injury with Nintedanib: A Pharmacovigilance-Pharmacokinetic Appraisal, file 69f80cdd-a0a4-4c80-80bc-ab3e66a45bce
|
13
|
|
Multiple sclerosis as an adverse drug reaction: clues from the FDA Adverse Event Reporting System, file e1dcb331-c79f-7715-e053-1705fe0a6cc9
|
13
|
|
European List of Essential Medicines for Medical Education: A protocol for a modified Delphi study, file 08f94740-858d-4530-9a0a-20e950a70f9d
|
12
|
|
Risk of hospitalization from drug-drug interactions in the Elderly: real-world evidence in a large administrative database, file e1dcb335-f680-7715-e053-1705fe0a6cc9
|
10
|
|
Liver Injury with Ulipristal Acetate: Exploring the Underlying Pharmacological Basis, file e1dcb336-c7d6-7715-e053-1705fe0a6cc9
|
10
|
|
Harmonizing and improving European education in prescribing: An overview of digital educational resources used in clinical pharmacology and therapeutics, file e1dcb339-94fc-7715-e053-1705fe0a6cc9
|
10
|
|
Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance, file e1dcb339-da19-7715-e053-1705fe0a6cc9
|
10
|
|
Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System, file b0a11f88-d7a2-4b48-a3ae-9841a77cd29c
|
8
|
|
Relationship between adverse drug reactions to antibacterial agents and the Klebsiella pneumoniae carbapenemase-producing (KPC) Klebsiella pneumoniae outbreak: Insight from a pharmacovigilance study, file e1dcb334-0b54-7715-e053-1705fe0a6cc9
|
8
|
|
SGLT2 inhibitors for heart failure with reduced ejection fraction: a real EMPEROR?, file e1dcb336-ddb0-7715-e053-1705fe0a6cc9
|
8
|
|
Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System, file e1dcb337-c79b-7715-e053-1705fe0a6cc9
|
8
|
|
EurOP2E – the European Open Platform for Prescribing Education, a consensus study among clinical pharmacology and therapeutics teachers, file e1dcb339-826a-7715-e053-1705fe0a6cc9
|
7
|
|
Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment, file 46fe2111-4d49-4e50-b12d-b45022612301
|
6
|
|
Phytoestrogens in postmenopause: the state of the art from a chemical, pharmacological and regulatory perspective, file e1dcb32c-ce26-7715-e053-1705fe0a6cc9
|
6
|
|
Serious adverse events with novel beta-lactam/beta-lactamase inhibitor combinations: a large-scale pharmacovigilance analysis, file 179816c5-e9d7-4c17-8984-2ce768475d8e
|
5
|
|
EurOP2E – the European Open Platform for Prescribing Education, a consensus study among clinical pharmacology and therapeutics teachers, file 24b3937f-0737-4c91-8001-bcc95738514d
|
5
|
|
Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system, file e1dcb336-f68a-7715-e053-1705fe0a6cc9
|
5
|
|
A clinical pharmacology and therapeutics teacher's guide to race-based medicine, inclusivity, and diversity, file f66739dd-9b4a-4689-a926-14c9fb9dd735
|
5
|
|
Liver Injury with Ulipristal Acetate: Exploring the Underlying Pharmacological Basis, file 283fb261-c43d-4dd8-8c7a-5af22d135f22
|
4
|
|
Deliberate Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System, file 9872e675-f479-47c9-9867-28b38909c2aa
|
4
|
|
Harmonizing and improving European education in prescribing: An overview of digital educational resources used in clinical pharmacology and therapeutics, file abf20940-ecd6-494d-aa73-d44cbd13a092
|
4
|
|
Assessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database, file e1dcb32d-1c38-7715-e053-1705fe0a6cc9
|
4
|
|
Drug- and herb-induced liver injury: Progress, current challenges and emerging signals of post-marketing risk, file e1dcb32d-e805-7715-e053-1705fe0a6cc9
|
4
|
|
Mesenchymal stromal cell-based therapy: Regulatory and translational aspects in gastroenterology, file e1dcb32f-acda-7715-e053-1705fe0a6cc9
|
4
|
|
Crystal nephropathy and amoxicillin: insights from international spontaneous reporting systems, file e1dcb33a-2f36-7715-e053-1705fe0a6cc9
|
4
|
|
A clinical pharmacology and therapeutics teacher's guide to race-based medicine, inclusivity, and diversity, file 4e89c35c-0490-4cb4-a7a4-a2cda3b68b4e
|
3
|
|
Amyotrophic Lateral Sclerosis as an Adverse Drug Reaction: A Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System, file 6123cec3-26d5-4009-92d8-fa4f5b109c33
|
3
|
|
Exploring the underlying mechanisms of drug-induced impulse control disorders: a pharmacovigilance-pharmacodynamic study, file 7b662054-0d67-4bd9-a369-d9a607f9600d
|
3
|
|
Serotonin syndrome by drug interactions with linezolid: clues from pharmacovigilance-pharmacokinetic/pharmacodynamic analysis, file d1f61c47-249c-4759-982f-56a112d821a4
|
3
|
|
Drug-Induced Renal Damage in Preterm Neonates: State of the Art and Methods for Early Detection, file e1dcb32d-ed91-7715-e053-1705fe0a6cc9
|
3
|
|
Risk–Benefit Profile of Direct-Acting Oral Anticoagulants in Established Therapeutic Indications: An Overview of Systematic Reviews and Observational Studies, file e1dcb32f-83bf-7715-e053-1705fe0a6cc9
|
3
|
|
Occurrence of Multiple Sclerosis After Drug Exposure: Insights From Evidence Mapping, file e1dcb330-9165-7715-e053-1705fe0a6cc9
|
3
|
|
Severe quetiapine voluntary overdose successfully treated with a new hemoperfusion sorbent, file e1dcb332-b41e-7715-e053-1705fe0a6cc9
|
3
|
|
Biomarkers of Kidney Injury in Very-low-birth-weight Preterm Infants: Influence of Maternal and Neonatal Factors, file e1dcb335-55dd-7715-e053-1705fe0a6cc9
|
3
|
|
Crystal nephropathy and amoxicillin: insights from international spontaneous reporting systems, file e1dcb33a-2f37-7715-e053-1705fe0a6cc9
|
3
|
|
Educational value of international and intercultural differences in prescribing: the international and interprofessional student-run clinic project, file 0602de6d-b36b-404b-b89f-925ba755e196
|
2
|
|
Development of a Network-Based Signal Detection Tool: The COVID-19 Adversome in the FDA Adverse Event Reporting System, file 1be23e9b-59ba-4baf-936b-bd717c99497f
|
2
|
|
Clinically Significant Drug Interactions Between Psychotropic Agents and Repurposed COVID-19 Therapies, file 4d0fd45c-44fd-41af-a935-95096d542061
|
2
|
|
Clinically Significant Drug Interactions Between Psychotropic Agents and Repurposed COVID-19 Therapies, file d5a912f4-315b-4939-a2de-a6ac15efed9f
|
2
|
|
Macrolides and Torsadogenic Risk: Emerging Issues from the FDA Pharmacovigilance Database, file e1dcb32c-623f-7715-e053-1705fe0a6cc9
|
2
|
|
Use of phytoestrogens and effects perceived by postmenopausal women: result of a questionnaire-based survey, file e1dcb32d-1c3d-7715-e053-1705fe0a6cc9
|
2
|
|
null, file e1dcb32d-dc84-7715-e053-1705fe0a6cc9
|
2
|
|
Stroke, Migraine and Triptans: From Bedside to Bench, file e1dcb32e-68fc-7715-e053-1705fe0a6cc9
|
2
|
|
Evolving Roles of Spontaneous Reporting Systems to Assess and Monitor Drug Safety, file e1dcb333-f0af-7715-e053-1705fe0a6cc9
|
2
|
|
µ-opioid receptor, β-endorphin, and cannabinoid receptor-2 are increased in the colonic mucosa of irritable bowel syndrome patients., file e1dcb334-0b2e-7715-e053-1705fe0a6cc9
|
2
|
|
Antipsychotics and Drug-Induced Liver Injury, file 070f3ae0-0fd7-483b-949e-f4ec46ad2278
|
1
|
|
Exploring the underlying mechanisms of drug-induced impulse control disorders: a pharmacovigilance-pharmacodynamic study, file 185cc669-d236-42f3-9712-502b2306e2b3
|
1
|
|
Drug-induced systemic lupus erythematosus: Should immune checkpoint inhibitors be added to the evolving list?, file 39a3b588-aefd-4061-84bb-e55ba8464ef8
|
1
|
|
Impact of nephrotoxic drugs on urinary biomarkers of renal function in very preterm infants, file 5d2f38c5-7814-4ff9-81e0-39b8f9ba6501
|
1
|
|
Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System, file c55c04d5-9141-4d2a-ac6d-aed2ce766968
|
1
|
|
Learning of clinical pharmacology by future prescribers in Bologna: Teachers' and students' reflections on the way forward, file d7bb6287-942e-45d9-a9fb-5ba4ad3f000a
|
1
|
|
Amyotrophic Lateral Sclerosis as an Adverse Drug Reaction: A Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System, file df709887-9684-4a0d-86e6-5c555ac5ad35
|
1
|
|
Cardiovascular events in statin recipients: a 3-year record-linkage study on prescription and hospital discharge databases, file e1dcb32c-0dda-7715-e053-1705fe0a6cc9
|
1
|
|
Interrupted time series analysis on the impact of dronedarone authorisation on Italian and Swedish antiarrhythmic prescriptions, file e1dcb32c-4044-7715-e053-1705fe0a6cc9
|
1
|
|
Nerve fiber outgrowth is increased in the intestinal mucosa of patients with irritable bowel syndrome, file e1dcb32d-1a83-7715-e053-1705fe0a6cc9
|
1
|
|
Lubiprostone: pharmacokinetic, pharmacodynamic, safety and regulatory aspects in the treatment of constipation-predominant irritable bowel syndrome, file e1dcb32d-1e65-7715-e053-1705fe0a6cc9
|
1
|
|
Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: Systematic review of observational studies, file e1dcb32d-ef29-7715-e053-1705fe0a6cc9
|
1
|
|
Comment on: “Pharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitus”, file e1dcb32d-f12a-7715-e053-1705fe0a6cc9
|
1
|
|
Social and clinical descriptors of antipsychotic prescription, file e1dcb32e-1bd0-7715-e053-1705fe0a6cc9
|
1
|
|
Evidence for the hERG Liability of Antihistamines, Antipsychotics, and Anti-Infective Agents: A Systematic Literature Review From the ARITMO Project, file e1dcb32f-7075-7715-e053-1705fe0a6cc9
|
1
|
|
Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems, file e1dcb331-0a5f-7715-e053-1705fe0a6cc9
|
1
|
|
Escherichia coli Nissle 1917 restores epithelial permeability alterations induced by irritable bowel syndrome mediators, file e1dcb332-3382-7715-e053-1705fe0a6cc9
|
1
|
|
Liver injury with drugs used for multiple sclerosis: A contemporary analysis of the FDA Adverse Event Reporting System, file e1dcb333-ca01-7715-e053-1705fe0a6cc9
|
1
|
|
Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System, file e1dcb333-f64f-7715-e053-1705fe0a6cc9
|
1
|
|
Reduced reporting of neuropsychiatric adverse events with tumor necrosis factor alpha inhibitors for hidradenitis suppurativa: caution before concluding for risk reduction., file e1dcb335-aded-7715-e053-1705fe0a6cc9
|
1
|
|
Signal of potentially protective drug–drug interactions from spontaneous reporting systems: proceed with caution, file e1dcb336-d3cd-7715-e053-1705fe0a6cc9
|
1
|
|
Serious Cutaneous Toxicities with Immune Checkpoint Inhibitors in the U.S. Food and Drug Administration Adverse Event Reporting System., file e1dcb338-9a38-7715-e053-1705fe0a6cc9
|
1
|
|
Developing medical artificial intelligence leaders: International university consortium approach, file e1dcb339-7438-7715-e053-1705fe0a6cc9
|
1
|
| Totale |
3.307 |